Study of peripheral BRAFV600E mutation as a possible novel marker for papillary thyroid carcinomas
Jin Young Kwak MD
Department of Radiology, Research Institute of Radiological Science, Yonsei, University College of Medicine, Seoul, Korea
Search for more papers by this authorJong Ju Jeong MD
Department of Surgery, Yonsei University College of Medicine, Seoul, Korea
Search for more papers by this authorSang–Wook Kang MD
Department of Surgery, Yonsei University College of Medicine, Seoul, Korea
Search for more papers by this authorSeulkee Park MD
Department of Surgery, Yonsei University College of Medicine, Seoul, Korea
Search for more papers by this authorJong Rak Choi MD
Department of Laboratory Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea
Search for more papers by this authorSeo–Jin Park MD
Department of Laboratory Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea
Search for more papers by this authorEun Kyung Kim MD
Department of Radiology, Research Institute of Radiological Science, Yonsei, University College of Medicine, Seoul, Korea
Search for more papers by this authorCorresponding Author
Woong Youn Chung MD
Department of Surgery, Yonsei University College of Medicine, Seoul, Korea
Department of Surgery, Yonsei University College of Medicine, 50 Yonsei-ro, Seodaemun-gu, 120-752 Seoul, Korea. E-mail: [email protected]Search for more papers by this authorJin Young Kwak MD
Department of Radiology, Research Institute of Radiological Science, Yonsei, University College of Medicine, Seoul, Korea
Search for more papers by this authorJong Ju Jeong MD
Department of Surgery, Yonsei University College of Medicine, Seoul, Korea
Search for more papers by this authorSang–Wook Kang MD
Department of Surgery, Yonsei University College of Medicine, Seoul, Korea
Search for more papers by this authorSeulkee Park MD
Department of Surgery, Yonsei University College of Medicine, Seoul, Korea
Search for more papers by this authorJong Rak Choi MD
Department of Laboratory Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea
Search for more papers by this authorSeo–Jin Park MD
Department of Laboratory Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea
Search for more papers by this authorEun Kyung Kim MD
Department of Radiology, Research Institute of Radiological Science, Yonsei, University College of Medicine, Seoul, Korea
Search for more papers by this authorCorresponding Author
Woong Youn Chung MD
Department of Surgery, Yonsei University College of Medicine, Seoul, Korea
Department of Surgery, Yonsei University College of Medicine, 50 Yonsei-ro, Seodaemun-gu, 120-752 Seoul, Korea. E-mail: [email protected]Search for more papers by this authorAbstract
Background
The BRAFV600E mutation can be detected peripherally in the serum of patients with thyroid cancer. The purpose of this study was to establish the value of detecting the peripheral BRAFV600E mutation as a serum tumor marker in this population.
Methods
In this study, we obtained 94 serum samples from patients with papillary thyroid cancer positive for the BRAFV600E mutation in the tumor itself. The serum samples were analyzed for BRAFV600E mutation using real-time polymerase chain reaction (PCR).
Results
Sixty-seven patients (71.3%) had papillary thyroid microcarcinoma and 26 patients (27.7%) had underlying lymphocytic thyroiditis. Forty-three patients (45.7%) were found to have stage III or stage IV thyroid cancer. None of the patients had a detectable serum BRAFV600E mutation.
Conclusion
We were unable to identify peripheral BRAFV600E mutations in patients with papillary thyroid cancer using real-time PCR. Further studies will be needed to validate our results using various diagnostic methods. © Wiley Periodicals Inc. Head Neck, 35: 1630–1633, 2013
REFERENCES
- 1Davies L, Welch HG. Increasing incidence of thyroid cancer in the United States, 1973–2002. JAMA 2006; 295: 2164–2167.
- 2Chen AY, Jemal A, Ward EM. Increasing incidence of differentiated thyroid cancer in the United States, 1988–2005. Cancer 2009; 115: 3801–3807.
- 3Leenhardt L, Grosclaude P, Chérié–Challine L; Thyroid Cancer Committee. Increased incidence of thyroid carcinoma in France: a true epidemic or thyroid nodule management effects? Report from the French Thyroid Cancer Committee. Thyroid 2004; 14: 1056–1060.
- 4Kim TY, Kim WB, Song JY, et al. The BRAF mutation is not associated with poor prognostic factors in Korean patients with conventional papillary thyroid microcarcinoma. Clin Endocrinol (Oxf) 2005; 63: 588–593.
- 5Renshaw AA. Papillary carcinoma of the thyroid ≤1.0 cm: rarely incidental or occult any more. Cancer 2005; 105: 217–219.
- 6 American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer,Cooper DS, Doherty GM, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009; 19: 1167–1214.
- 7Cibas ES, Ali SZ. The Bethesda System for reporting thyroid cytopathology. Thyroid 2009; 19: 1159–1165.
- 8Kwak JY, Koo H, Youk JH, et al. Value of US correlation of a thyroid nodule with initially benign cytologic results. Radiology 2010; 254: 292–300.
- 9Yoon JH, Kwak JY, Kim EK, et al. How to approach thyroid nodules with indeterminate cytology. Ann Surg Oncol 2010; 17: 2147–2155.
- 10Centre NCI. Annual Report of the Korea Central Cancer Registry. Available at: http://www.cancer.go.kr/cms/cancer/cancer_is/04/1191182_1753.html. Accessed June 2010.
- 11Moon HJ, Kwak JY, Kim EK, et al. The role of BRAFV600E mutation and ultrasonography for the surgical management of a thyroid nodule suspicious for papillary thyroid carcinoma on cytology. Ann Surg Oncol 2009; 16: 3125–3131.
- 12Kim SK, Hwang TS, Yoo YB, et al. Surgical results of thyroid nodules according to a management guideline based on the BRAF(V600E) mutation status. J Clin Endocrinol Metab 2011; 96: 658–664.
- 13Lee HJ, Choi J, Hwang TS, Shong YK, Hong SJ, Gong G. Detection of BRAF mutations in thyroid nodules by allele-specific PCR using a dual priming oligonucleotide system. Am J Clin Pathol 2010; 133: 802–808.
- 14Chuang TC, Chuang AY, Poeta L, Koch WM, Califano JA, Tufano RP. Detectable BRAF mutation in serum DNA samples from patients with papillary thyroid carcinomas. Head Neck 2010; 32: 229–234.
- 15Cradic KW, Milosevic D, Rosenberg AM, Erickson LA, McIver B, Grebe SK. Mutant BRAF(T1799A) can be detected in the blood of papillary thyroid carcinoma patients and correlates with disease status. J Clin Endocrinol Metab 2009; 94: 5001–5009.
- 16Kwak JY, Han KH, Yoon JH, et al. BRAFV600E mutation testing in fine needle aspirates of thyroid nodules: potential value of real-time PCR. Ann Clin Lab Sci 2012; 42: 258–265.
- 17Kim EK, Park CS, Chung WY, et al. New sonographic criteria for recommending fine-needle aspiration biopsy of nonpalpable solid nodules of the thyroid. AJR Am J Roentgenol. 2002; 178: 687–691.
- 18Wellbrock C, Karasarides M, Marais R. The RAF proteins take centre stage. Nat Rev Mol Cell Biol 2004; 5: 875–885.
- 19Xing M, Tufano RP, Tufaro AP, et al. Detection of BRAF mutation on fine needle aspiration biopsy specimens: a new diagnostic tool for papillary thyroid cancer. J Clin Endocrinol Metab 2004; 89: 2867–2872.
- 20Kimura ET, Nikiforova MN, Zhu Z, Knauf JA, Nikiforov YE, Fagin JA. High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res 2003; 63: 1454–1457.
- 21Kim KH, Kang DW, Kim SH, Seong IO, Kang DY. Mutations of the BRAF gene in papillary thyroid carcinoma in a Korean population. Yonsei Med J 2004; 45: 818–821.
- 22Namba H, Nakashima M, Hayashi T, et al. Clinical implication of hot spot BRAF mutation, V599E, in papillary thyroid cancers. J Clin Endocrinol Metab 2003; 88: 4393–4397.
- 23Xing M, Westra WH, Tufano RP, et al. BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. J Clin Endocrinol Metab 2005; 90: 6373–6379.
- 24Kim J, Giuliano AE, Turner RR, et al. Lymphatic mapping establishes the role of BRAF gene mutation in papillary thyroid carcinoma. Ann Surg 2006; 244: 799–804.
- 25Lee JH, Lee ES, Kim YS, Won NH, Chae YS. BRAF mutation and AKAP9 expression in sporadic papillary thyroid carcinomas. Pathology 2006; 38: 201–204.
- 26Lupi C, Giannini R, Ugolini C, et al. Association of BRAF V600E mutation with poor clinicopathological outcomes in 500 consecutive cases of papillary thyroid carcinoma. J Clin Endocrinol Metab 2007; 92: 4085–4090.
- 27Elisei R, Ugolini C, Viola D, et al. BRAF (V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study. J Clin Endocrinol Metab 2008; 93: 3943–3949.
- 28Nikiforov YE, Steward DL, Robinson–Smith TM, et al. Molecular testing for mutations in improving the fine-needle aspiration diagnosis of thyroid nodules. J Clin Endocrinol Metab 2009; 94: 2092–2098.
- 29Fugazzola L, Puxeddu E, Avenia N, et al. Correlation between B-RAFV600E mutation and clinico-pathologic parameters in papillary thyroid carcinoma: data from a multicentric Italian study and review of the literature. Endocr Relat Cancer 2006; 13: 455–464.
- 30Moon HJ, Kim EK, Chung WY, Choi JR, Yoon JH, Kwak JY. Diagnostic value of BRAF(V600E) mutation analysis of thyroid nodules according to ultrasonographic features and the time of aspiration. Ann Surg Oncol 2011; 18: 792–799.
- 31Sedliarou I, Saenko V, Lantsov D, et al. The BRAFT1796A transversion is a prevalent mutational event in human thyroid microcarcinoma. Int J Oncol 2004; 25: 1729–1735.
- 32Lee X, Gao M, Ji Y, et al. Analysis of differential BRAF(V600E) mutational status in high aggressive papillary thyroid microcarcinoma. Ann Surg Oncol 2009; 16: 240–245.
- 33Kwak JY, Kim EK, Kim JK, et al. Dual priming oligonucleotide-based multiplex PCR analysis for detection of BRAFV600E mutation in FNAB samples of thyroid nodules in BRAFV600E mutation-prevalent area. Head Neck 2010; 32: 490–498.
- 34Kim SW, Lee JI, Kim JW, et al. BRAFV600E mutation analysis in fine-needle aspiration cytology specimens for evaluation of thyroid nodule: a large series in a BRAFV600E-prevalent population. J Clin Endocrinol Metab 2010; 95: 3693–3700.
- 35Park SY, Park YJ, Lee YJ, et al. Analysis of differential BRAF(V600E) mutational status in multifocal papillary thyroid carcinoma: evidence of independent clonal origin in distinct tumor foci. Cancer 2006; 107: 1831–1838.
- 36Chung KW, Yang SK, Lee GK, et al. Detection of BRAFV600E mutation on fine needle aspiration specimens of thyroid nodule refines cyto-pathology diagnosis, especially in BRAF600E mutation-prevalent area. Clin Endocrinol (Oxf) 2006; 65: 660–666.
- 37Kim TY, Kim WB, Rhee YS, et al. The BRAF mutation is useful for prediction of clinical recurrence in low-risk patients with conventional papillary thyroid carcinoma. Clin Endocrinol (Oxf) 2006; 65: 364–368.
- 38Han MA, Choi KS, Lee HY, Kim Y, Jun JK, Park EC. Current status of thyroid cancer screening in Korea: results from a nationwide interview survey. Asian Pac J Cancer Prev 2011; 12: 1657–1663.
- 39Gharib H, Papini E, Paschke R, et al. American Association of Clinical Endocrinologists, Associazione Medici Endocrinologi, and European Thyroid Association medical guidelines for clinical practice for the diagnosis and management of thyroid nodules: executive summary of recommendations. Endocr Pract 2010; 16: 468–475.
- 40Moon WJ, Baek JH, Jung SL, et al. Ultrasonography and the ultrasound-based management of thyroid nodules: consensus statement and recommendations. Korean J Radiol 2011; 12: 1–14.
- 41Frates MC, Benson CB, Charboneau JW, et al. Management of thyroid nodules detected at US: Society of Radiologists in Ultrasound consensus conference statement. Radiology 2005; 237: 794–800.
- 42Chow SM, Law SC, Chan JK, Au SK, Yau S, Lau WH. Papillary microcarcinoma of the thyroid-prognostic significance of lymph node metastasis and multifocality. Cancer 2003; 98: 31–40.
- 43Noguchi S, Yamashita H, Uchino S, Watanabe S. Papillary microcarcinoma. World J Surg 2008; 32: 747–753.
- 44Yun M, Noh TW, Cho A, et al. Visually discernible [18F]fluorodeoxyglucose uptake in papillary thyroid microcarcinoma: a potential new risk factor. J Clin Endocrinol Metab 2010; 95: 3182–3188.
- 45Kwak JY, Kim EK, Chung WY, Moon HJ, Kim MJ, Choi JR. Association of BRAFV600E mutation with poor clinical prognostic factors and US features in Korean patients with papillary thyroid microcarcinoma. Radiology 2009; 253: 854–860.
- 46Shinozaki M, O'Day SJ, Kitago M, et al. Utility of circulating B-RAF DNA mutation in serum for monitoring melanoma patients receiving biochemotherapy. Clin Cancer Res 2007; 13: 2068–2074.
- 47Yeo MK, Liang ZL, Oh T, et al. Pyrosequencing cut-off value identifying BRAFV600E mutation in fine needle aspiration samples of thyroid nodules. Clin Endocrinol (Oxf) 2011; 75: 555–560.
Citing Literature
